IL1B and chronic kidney disease: The previous studies demonstrated that ATL-III significantly prevented cell death and cell membrane damage in a dose-dependent manner [20] and inhibited the production of proinflammatory cytokines, such as IL-6, IL-1β, TNF-α, and IL-8 [21], which was similar with our results in CKD model rats.